File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015

TitleTrends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015
Authors
KeywordsStatin
Prescribing
Prescribing
Initiation
Dosing
Primary prevention
Secondary prevention
Issue Date2019
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis
Citation
Atherosclerosis, 2019, v. 280, p. 174-182 How to Cite?
AbstractBackground and aims: Clinical practice guidelines recommend specific statin doses for the primary and secondary prevention of cardiovascular disease. Little is known about how statin utilization and dosing have evolved over time in Hong Kong. The aim of this study was to describe trends in statin prevalence, initiation, and dosing from 2004 to 2015. Methods: Patients receiving public health services, who were prescribed a statin, were included if they received a lipid test at a single center (n = 58,672). Using the territory-wide electronic health record, prescribed daily statin dose, nondaily dose frequency, and statin dose intensity were determined for statin prescriptions from 2004 to 2015. Statin prescription prevalence and initiation rates were estimated using the appropriate at-risk population in the hospital catchment area as the denominator. Prescribed daily doses were stratified by primary or secondary cardiovascular prevention status to assess changes in statin dosing over time. Results: The prescription prevalence of statins was higher in 2015 (8.68%; 95% CI, 8.60%–8.75%) as compared with 2004 (1.82%; 95% confidence interval [CI], 1.78%–1.86%). Initiation rates for new statin users increased from 2004 to 2013. High-intensity statins were infrequently prescribed. New users generally had higher statin initiation rates for primary prevention. There were small increases in the prescribed daily doses of statins. Nondaily statin dosing was infrequent (0.42% of all prescriptions). Conclusions: The prevalence and initiation of statin prescriptions increased in Hong Kong, and was in part driven by low-intensity statins for the primary prevention of cardiovascular disease.
Persistent Identifierhttp://hdl.handle.net/10722/275084
ISSN
2019 Impact Factor: 3.919
2015 SCImago Journal Rankings: 1.819
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBlais, JE-
dc.contributor.authorChan, EW-
dc.contributor.authorLaw, SWY-
dc.contributor.authorMok, MT-
dc.contributor.authorHuang, D-
dc.contributor.authorWong, ICK-
dc.contributor.authorSiu, CW-
dc.date.accessioned2019-09-10T02:35:07Z-
dc.date.available2019-09-10T02:35:07Z-
dc.date.issued2019-
dc.identifier.citationAtherosclerosis, 2019, v. 280, p. 174-182-
dc.identifier.issn0021-9150-
dc.identifier.urihttp://hdl.handle.net/10722/275084-
dc.description.abstractBackground and aims: Clinical practice guidelines recommend specific statin doses for the primary and secondary prevention of cardiovascular disease. Little is known about how statin utilization and dosing have evolved over time in Hong Kong. The aim of this study was to describe trends in statin prevalence, initiation, and dosing from 2004 to 2015. Methods: Patients receiving public health services, who were prescribed a statin, were included if they received a lipid test at a single center (n = 58,672). Using the territory-wide electronic health record, prescribed daily statin dose, nondaily dose frequency, and statin dose intensity were determined for statin prescriptions from 2004 to 2015. Statin prescription prevalence and initiation rates were estimated using the appropriate at-risk population in the hospital catchment area as the denominator. Prescribed daily doses were stratified by primary or secondary cardiovascular prevention status to assess changes in statin dosing over time. Results: The prescription prevalence of statins was higher in 2015 (8.68%; 95% CI, 8.60%–8.75%) as compared with 2004 (1.82%; 95% confidence interval [CI], 1.78%–1.86%). Initiation rates for new statin users increased from 2004 to 2013. High-intensity statins were infrequently prescribed. New users generally had higher statin initiation rates for primary prevention. There were small increases in the prescribed daily doses of statins. Nondaily statin dosing was infrequent (0.42% of all prescriptions). Conclusions: The prevalence and initiation of statin prescriptions increased in Hong Kong, and was in part driven by low-intensity statins for the primary prevention of cardiovascular disease.-
dc.languageeng-
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis-
dc.relation.ispartofAtherosclerosis-
dc.subjectStatin-
dc.subjectPrescribing-
dc.subjectPrescribing-
dc.subjectInitiation-
dc.subjectDosing-
dc.subjectPrimary prevention-
dc.subjectSecondary prevention-
dc.titleTrends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015-
dc.typeArticle-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailLaw, SWY: swylaw@hku.hk-
dc.identifier.emailHuang, D: huangduo@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hk-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authoritySiu, CW=rp00534-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.atherosclerosis.2018.11.015-
dc.identifier.pmid30529830-
dc.identifier.scopuseid_2-s2.0-85057855198-
dc.identifier.hkuros303003-
dc.identifier.volume280-
dc.identifier.spage174-
dc.identifier.epage182-
dc.identifier.isiWOS:000456421100023-
dc.publisher.placeIreland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats